Full-Time

Clinical Pharmacy Specialist

Ambulatory Cardiology

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center

10,001+ employees

Teaching hospital delivering patient-centered medical care

Compensation Overview

$128k - $162.3k/yr

Burlington, MA, USA

Hybrid

Hybrid schedule with required on-site work in Burlington, Massachusetts.

Bachelor's, Master's

Category
Medical, Clinical & Veterinary (1)
Required Skills
Microsoft Office
Word/Pages/Docs
Electronic Health Records (EHR)
Excel/Numbers/Sheets
Microsoft Outlook
PowerPoint/Keynote/Slides

Get referred to Beth Israel Deaconess Medical Center

See people who can refer or advise you

Requirements
  • A Bachelor's degree in Pharmacy is required.
  • Registration as a Massachusetts Pharmacist is required.
  • One to three years of related work experience is required.
  • Completion of a PGY1 accredited pharmacy residency or at least three years of clinical pharmacy experience in a hospital setting is required.
  • Obtain one or more certifications within 18 months of hire: Certified Specialty Pharmacist, Board Certification in Pharmacotherapy, or Ambulatory Care Pharmacy certification.
  • Understanding of insurance and adjudication processes.
  • Experience with computer systems, including web-based applications and Microsoft Office applications such as Outlook, Word, Excel, PowerPoint, or Access.
  • Ability to make decisions guided by precedents, policies, and objectives, including decisions affecting a department or functional area.
  • Ability to address highly varied, complex, and often non-recurring problems using staff input, innovative approaches, creative techniques, and Lean diagnostic techniques.
  • Ability to set goals and determine how to accomplish defined results with some guidelines.
  • Ability to summarize and communicate moderately complex information in varied written formats in English.
  • Ability to comprehend and communicate complex verbal information in English to medical center staff, patients, families, and external customers.
  • In-depth knowledge of concepts, practices, and policies and the ability to apply them in complex, varied situations.
  • Ability to act as a team leader for small projects or work groups and improve workflows.
  • Ability to provide patient care across neonatal, youth, young adult, middle-age, and elderly age groups.
  • Ability to perform light work, including frequently exerting up to 20 pounds of force and standing or moving through the hospital campus.
  • Maintain credentials in accordance with the Massachusetts Board of Registration in Pharmacy.
Responsibilities
  • Practice pharmacy in accordance with Massachusetts pharmacy laws and regulations, Department of Public Health requirements, U.S. Food and Drug Administration requirements, Drug Enforcement Administration requirements, and departmental policies and procedures.
  • Monitor patients in a specific unit or specialty service by collecting patient-specific data, interpreting drug-related laboratory data, performing relevant physical assessments, interviewing patients, and identifying therapy goals.
  • Develop, administer, and improve ambulatory pharmacy programs and services, including drug use evaluations, adverse drug reaction reporting, clinic development and management, and business plan creation.
  • Under protocol, initiate, adjust, monitor, and recommend changes in drug therapy based on patient interviews, objective monitoring parameters, physical assessments, adverse-effect management, medication profiles, and medical records.
  • Document clinical interventions in the electronic health record in a timely and professional manner.
  • Coordinate and interpret laboratory monitoring of drug therapy, including serum drug levels, electrolytes, and other approved drug-related laboratory testing.
  • Monitor patients to evaluate and optimize outcomes, drug utilization, and compliance; detect or minimize adverse drug reactions; and eliminate unnecessary drug use and duplication.
  • Coordinate continuing education for medical and nursing staff, orient new employees on pharmacy practices and procedures, submit content to pharmacy newsletters, participate in journal clubs, and provide in-service education.
  • Precept PGY1 and PGY2 pharmacy residents and pharmacy students and contribute to staff development in the specialty practice area.
  • Collaborate with clinical pharmacy specialists to develop pharmacy skills among pharmacy staff by teaching and modeling those skills.
Desired Qualifications
  • Doctoral degree in Pharmacy.
  • Pharmacy residency PGY2 specialty experience, fellowship, equivalent experience, or 5+ years of clinical pharmacy experience.
  • Knowledge of complex or chronic disease states and therapies used within specialty pharmacy, including Primary Care, Oncology, Transplant, Infectious Disease including HIV, Multiple Sclerosis, Rheumatoid Arthritis, Gastroenterology, Hepatology, Dermatology, Cardiology, Pulmonary, Allergy, or inflammatory conditions.
Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center

View

Beth Israel Deaconess Medical Center (BIDMC) serves as a teaching hospital in Boston affiliated with Harvard Medical School, offering a wide range of medical services across inpatient, emergency, outpatient, and urgent care. Its care model centers on delivering high-quality medical treatment to patients, supported by patient access initiatives like OpenNotes, which lets patients view clinicians’ notes online to improve understanding and engagement in their care. The hospital also supports education and research through its affiliation with Harvard, attracting funding for studies and training programs. BIDMC differentiates itself through its patient-centered approach, active patient engagement tools, and a broad network of urgent care centers and outpatient services that extend access to healthcare. The goal is to provide comprehensive, accessible, evidence-based medical care while advancing medical education and research.

Company Size

10,001+

Company Stage

Grant

Total Funding

$5.4M

Headquarters

Boston, Massachusetts

Founded

1996

Get referred to Beth Israel Deaconess Medical Center

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • BIDMC won a June 2026 NIH R01 to study ADAMTS13 across thrombotic disease.
  • BIDMC expanded NeuroXT Alzheimer's biomarker work in May 2026 after initial validation success.
  • BIDMC remains top-ranked in 2025-2026 U.S. News, including third in Massachusetts.

What critics are saying

  • Resident doctors unionized in 2025, and their 2026 contract raises first-year pay to $92,929.
  • BILH CEO Kevin Tabb exits in 2027, creating leadership churn during the Dana-Farber buildout.
  • A failed BILH oncology integration would divert referrals, talent, and capital to Mass General.

What makes Beth Israel Deaconess Medical Center unique

  • Harvard Medical School affiliation anchors BIDMC's specialty reputation and research recruiting power.
  • OpenNotes transparency still differentiates BIDMC's patient engagement model nationwide.
  • Dana-Farber cancer hospital construction links BIDMC to a 300-bed oncology platform, opening 2031.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Harvard Medical Faculty Physicians
Aug 6th, 2026
BIDMC nationally recognized by U.S. News & World Report

BIDMC nationally recognized by U.S. News & world report. BIDMC has once again been recognized as a leading hospital in Boston and the nation. The hospital was nationally ranked in eight adult specialties - OBGYN (#4), diabetes and endocrinology - BIDMC and the Joslin Diabetes Center (#9), gastroenterology and GI surgery (#26), cancer care (#28), pulmonary and lung surgery (#26), geriatrics (#36 - tied), cardiology, heart, and vascular surgery (#35-tied), and neurology and neurosurgery (#31). A special congratulations to the Department of Obstetrics and Gynecology, which achieved its highest-ever placement in the US News rankings, earning the No. 4 spot nationally and securing its first top five ranking. Congratulations to all HMFP physicians and staff whose clinical excellence, dedication, and commitment to our patients, communities, and one another are reflected in these prestigious honors. Click here for full coverage.

Harvard Medical Faculty Physicians
Aug 6th, 2026
BIDMC OB/GYN Program Ranked #4 in the Nation by U.S. News & World Report

BIDMC OB/GYN program ranked #4 in the nation by U.S. News & World Report. Beth Israel Deaconess Medical Center's (BIDMC) Department of Obstetrics and Gynecology has been ranked #4 in the nation for Obstetrics & Gynecology care in U.S. News & World Report's 2026-2027 Best Hospitals rankings. The department was also recognized as Nationally High Performing in Gynecologic Cancer Surgery. "This recognition belongs to our entire department. Every day, our team brings our core values of humanity, excellence, and equity to life through the care we provide," said Blair Wylie, MD, MPH, Chair of the Department of Obstetrics and Gynecology at BIDMC. "From routine care to the most complex needs, our patients trust us to be with them at every stage of their journey. It is a privilege to care for them, and they are the reason this work and this recognition are so meaningful." The U.S. News & World Report recognition is part of a broader showing for BIDMC in this year's rankings. The hospital placed among the top 50 hospitals nationwide in eight specialties, and was named the #3 best hospital in the Boston region and #3 best hospital in Massachusetts. Across its specialties and procedures and conditions, BIDMC received 20 high-performing ratings in total. U.S. News evaluated nearly 4,500 hospitals across 14 adult specialties and 23 procedures and conditions for this year's rankings; fewer than half earned recognition in any of the 37 areas of care assessed. To determine the Best Hospitals rankings, U.S. News analyzed each hospital's performance using objective measures such as risk-adjusted mortality rates, preventable complications, and patient experience, drawing on data from more than 800 million patient care records. More information on the U.S. News & World Report Best Hospitals rankings, including the full specialty rankings and procedures and conditions methodologies, is available at health.usnews.com/best-hospitals.

Beth Israel Deaconess Medical Center
Aug 5th, 2026
Beth Israel Deaconess Medical Center nationally recognized by U.S. News & World Report.

Beth Israel Deaconess Medical Center nationally recognized by U.S. News & World Report. August 05, 2026 BIDMC named in top three hospitals in Massachusetts. Boston, MA - Beth Israel Deaconess Medical Center (BIDMC) has been recognized for its high-quality care by U.S. News & World Report's 2026-2027 Best Hospitals edition, placing in the top 50 hospitals nationwide in eight specialties. BIDMC was ranked in the top 10 nationwide for two of those specialties: obstetrics & gynecology and diabetes & endocrinology. BIDMC was also named as the #3 best hospital in the Boston Metro Area region and #3 best hospital in Massachusetts. "Being again nationally recognized by U.S. News & World Report reflects the high-quality care teams across BIDMC provide to patients and their families," said Pete Healy, president, BIDMC & divisional president, Metro Boston, Beth Israel Lahey Health. "I am thankful for the commitment of our physicians, nurses, and staff to excellent and compassionate care." The eight specialties that BIDMC received national rankings include: * Obstetrics & Gynecology * Diabetes & Endocrinology * Gastroenterology & GI surgery * Pulmonology & Lung surgery * Cancer Care * Neurology & Neurosurgery * Heart & Vascular * Geriatrics The hospital received 20 high-performing ratings across specialties and procedures & conditions, including aortic valve surgery; colon cancer surgery; ear, nose & throat surgery; gynecological cancer surgery; heart bypass surgery; heart failure; kidney failure; leukemia, lymphoma & myeloma; lung cancer surgery; prostate cancer surgery; stroke; and urology. U.S. News evaluated nearly 4,500 hospitals across 14 adult specialties and 23 procedures and conditions; less than half earned recognition in any of those 37 areas of care. To determine the Best Hospitals, U.S. News analyzed each hospital's performance based on objective measures such as risk-adjusted mortality rates, preventable complications and patient experience. The Best Hospitals Specialty rankings methodology and Procedures & Conditions ratings methodology measure patient outcomes using data from over 800 million records of patient care. About Beth Israel Deaconess Medical Center. Beth Israel Deaconess Medical Center is a leading academic medical center, where extraordinary care is supported by high-quality education and research. BIDMC is a teaching affiliate of Harvard Medical School, and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding. BIDMC is the official hospital of the Boston Red Sox. Beth Israel Deaconess Medical Center is a part of Beth Israel Lahey Health, a healthcare system that brings together academic medical centers and teaching hospitals, community and specialty hospitals, more than 4,700 physicians and 39,000 employees in a shared mission to expand access to great care and advance the science and practice of medicine through groundbreaking research and education. Director of Media Relations Sarah finlaw. Please note: The contact information above is for journalists and news media only. For patient care and all other inquiries, please contact your doctor or BIDMC directly.

Harvard Medical Faculty Physicians
Jun 25th, 2026
Scott Rotig, MD, PhD, Joins Pathology as New BIDMC Vice Chair of Hematopathology

Scott rotig, MD, PhD, joins Pathology as new BIDMC Vice Chair of Hematopathology. Scott J. Rodig, MD, PhD is an internationally recognized hematopathologist, physician-scientist, and academic leader has joined the BIDMC Department of Pathology as Vice Chair of Hematopathology, and new position for the department. A Professor of Pathology at Harvard Medical School and an attending pathologist at Brigham and Women's Hospital and Dana-Farber Cancer Institute, Dr. Rodig brings more than two decades of clinical, research, and leadership experience at the forefront of hematologic malignancies. He has authored over 350 peer-reviewed publications, ranks among the top 1% of most-cited researchers in clinical medicine, and has played a pivotal role in discoveries and diagnostic innovations that have shaped modern lymphoma care. In his new role, Dr. Rodig will lead and strengthen collaboration between Dana-Farber's Hematologic Malignancies programs and BIDMC Pathology, advancing integrated clinical care, translational research, and education.

AllSci
Jun 25th, 2026
BIDMC wins NIH grant to study ADAMTS13 deficiency beyond rare clotting disorder.

BIDMC wins NIH grant to study ADAMTS13 deficiency beyond rare clotting disorder. June 25, 2026 Beth Israel Deaconess Medical Center (BIDMC) has received a USD 1.63 million NIH R01 grant from the National Heart, Lung, and Blood Institute to investigate ADAMTS13 deficiency across a spectrum of thrombotic disorders - research that carries direct clinical relevance following the FDA approval of recombinant ADAMTS13 (Takeda's Adzynma) for immune thrombotic thrombocytopenic purpura (iTTP). The award funds two parallel lines of inquiry. The first leverages the Harvard TMA Research Collaborative (HTRC), a large single-center iTTP registry assembled by BIDMC investigators, to build predictive models for relapse, refractoriness, and mortality in iTTP patients. The grant also supports the first genome-wide association and admixture mapping studies in iTTP, aimed at identifying germline variants that may explain the disproportionate disease burden observed in certain populations. The second line extends beyond iTTP: using genomic and proteomic data from approximately 800,000 individuals in the UK Biobank and NIH All of Us datasets, the team will examine whether moderate ADAMTS13 deficiency - activity between 10% and 70%, versus the severe deficiency that defines iTTP - contributes to common macrovascular events including stroke, myocardial infarction, peripheral artery disease, and venous thromboembolism. ADAMTS13 cleaves ultra-large von Willebrand factor multimers, preventing pathological platelet aggregation in the microvasculature. In iTTP, severe enzyme deficiency drives diffuse microvascular thrombosis and end-organ damage. The hypothesis that moderate deficiency may also elevate risk for common thrombotic events remains unproven at population scale - making the large multiomic analysis a central scientific contribution of this award. The work could expand the clinical relevance of ADAMTS13 beyond rare thrombotic disease. Recombinant ADAMTS13 is now approved, and if population-scale data indicate that moderate deficiency contributes to stroke or myocardial infarction, the therapeutic and screening implications could extend well beyond the rare iTTP indication. Principal investigator Pavan K. Bendapudi has published on statistical modeling in iTTP and population-scale hemostasis datasets, positioning the group to execute both the registry-based and biobank-scale components of this work. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/